Lupin receives USFDA’s approval for Albendazole Tablets

Lupin receives USFDA’s approval for Albendazole Tablets

182
Medicine Tablet
Picture: Pixabay

Pharma major Lupin announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories.

Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of:

Also read: BSV receives approval from DCGI for clinical study on Ulinastatin

  • Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm
  • Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm

Albendazole Tablets USP (RLD: Albenza) had an annual sales of approximately USD 34 million in the US (IQVIA MAT April 2020).

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.